Michael John Munchhof

This inventor holds 53 USPTO granted patents and 37 published patent applications, plus 6 CIPO patents and 9 EPO patents, primarily in PRMT5 Inhibitors (CPC class C07D). Top assignees: Epizyme, Inc., Pfizer Corporation, Pfizer Products Inc.. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael John Munchhof. Retrieved from https://idiyas.com/inventor/michael-john-munchhof

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 37)

% Patents Active = 69.8

CIPO Patents = 6 (Patent Applications = 24)

EPO Patents = 9 (Patent Applications = 33)

Average Co-Inventor Count = 3.2

ph-index = 19

Forward Citations = 1,008(Granted Patents)

Forward Citations (Not Self Cited) = 760(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

5. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

PRMT5 Inhibitors

Substituted Indoles

Isoxazole Compounds

Benzimidazole Derivatives

Pyrrolo[2,3-D]Pyrimidine

TGF Inhibitors

Chiral Salt Resolution

Substituted Piperidine

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116358 - Substituted indoles and methods of use thereof (2024-10-15),

2. 10980794 - PRMT5 inhibitors and uses thereof (2021-04-20),

3. 10653693 - PRMT5 inhibitors and uses thereof (2020-05-19),

4. 10577363 - Substituted piperidine compounds (2020-03-03),

5. 10428029 - Isoxazole carboxamide compounds (2019-10-01),

6. 10391089 - PRMT5 inhibitors and uses therof (2019-08-27),

7. 10307413 - Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof (2019-06-04),

8. 10266526 - Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer (2019-04-23),

9. 10150758 - PRMT5 inhibitors and uses thereof (2018-12-11),

10. 10118918 - PRMT5 inhibitors and uses thereof (2018-11-06),

11. 10106510 - Substituted isoxazoles for treating cancer (2018-10-23),

12. 9908887 - PRMT5 inhibitors and uses thereof (2018-03-06),

13. 9777008 - PRMT5 inhibitors and uses thereof (2017-10-03),

14. 9765068 - PRMT5 inhibitors and uses thereof (2017-09-19),

15. 9745291 - PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof (2017-08-29),

Title: Michael John Munchhof: Pioneering Innovations in Cancer Treatment

Introduction: Michael John Munchhof, a distinguished inventor hailing from Salem, CT, has established himself as a trailblazer in the field of medicinal chemistry, with an impressive portfolio of 52 patents to his name.

Latest Patents: Among his recent achievements are groundbreaking patents for PRMT5 inhibitors and their applications in treating PRMT5-mediated disorders, particularly cancer. These compounds, along with their pharmaceutical compositions, have shown promising results in inhibiting PRMT5 activity, marking a significant advancement in cancer therapy.

Career Highlights: Munchhof's illustrious career includes tenure at renowned pharmaceutical giants like Pfizer Corporation and Epizyme, Inc. At these esteemed organizations, he has contributed significantly to the development of novel drug compounds and innovative treatment modalities for various medical conditions.

Collaborations: Throughout his career, Munchhof has collaborated with esteemed professionals in the field, including notable colleagues Richard Chesworth and Kenneth William Duncan. This spirit of collaboration has been instrumental in driving forward his innovative research and patent applications.

Conclusion: Michael John Munchhof's relentless pursuit of excellence and his groundbreaking contributions to the field of medicinal chemistry underscore his status as a visionary inventor. His commitment to advancing cancer treatment through innovative drug development serves as a testament to his enduring impact on the healthcare industry.

Profile summary based on public USPTO records.